EnduRx is a preclinical company advancing an actively-targeted macromolecule-based drug delivery system with initial focus on hard-to-treat solid tumors. In collaboration with MD Anderson Houston, Endurx has been awarded various grant funding to develop a novel therapeutic for triple-negative breast cancer to the point of pre-IND meeting. Although little of administered drug actually reaches the tumors, as a treatment of cancer chemotherapy still relies on delivering a highly-toxic drug throughout the entire body with adverse side effects that can be horrific. The novel delivery system developed and offered by Endurx rapidly transports drug to the tumor micro-environment This rapid transport and high specificity of delivery can improve the effectiveness of the drug while greatly reducing adverse side effects. Promising data was obtained in mouse models of triple-negative breast cancer and glioblastoma, two hard-to-treat cancers with poor prognosis for patients. EnduRx is advancing the delivery system into IND-enabling activities with efficacy in human subjects in the foreseeable future. Application of the delivery system to formulation of approved or developmental drugs offers improved effectiveness and better patient experience, and could provide patent life extension.
